Title:Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease
Volume: 18
Issue: 6
Author(s): Cui Huo, Lei Wu, Zhiqiang Jiang, Jiacheng Yang, Zhouyu Wang, Yuzhi Li and Shan Qian*
Affiliation:
- Department of Biology and Medicine, College of Food and Bioengineering, Xihua University, Chengdu 610039, China
Keywords:
Neurodegenerative diseases, prodrug strategies, oral bioavailability, the brain permeability, alzheimer's disease, parkinson's disease.
Abstract: Background: Alzheimer's disease (AD) and Parkinson's (PD) disease are common neurodegenerative
conditions of the Central Nervous System (CNS). Thus, these diseases have only been
treated symptomatically since no approved drug is available that provides a complete cure.
Objectives: Through reading relevant literatures published at home and abroad, the method and significance
of prodrug strategy to increase the efficacy of ad and pd drugs were discussed.
Methods: The biological mechanisms and currently approved drugs for both diseases have been discussed,
revealing that most of these treatments utilized existing prodrug design strategies, including
increased lipophilicity, and the use of transporters mediation and bio-oxidation to improve oral bioavailability
and brain permeability.
Results: The purpose of this paper is to review the research progress in the treatment of Neurodegenerative
Diseases (NDDS), especially ad and pd, using the prodrug strategy. The research of drug
bioavailability and the prodrug strategy of cns targeted drug delivery lay the foundation for drug
development to treat these diseases.
Conclusion: The use of prodrug strategies provides important opportunities for the development of
novel therapies for ad and pd.